Michael Hanna

The urinary proteome and metabonome differ from normal in adults with mitochondrial disease

Publisher: Elsevier BV

Date: 03-2015

DOI: 10.1038/KI.2014.297

Abstract: We studied the extent and nature of renal involvement in a cohort of 117 adult patients with mitochondrial disease, by measuring urinary retinol-binding protein (RBP) and albumin established markers of tubular and glomerular dysfunction, respectively. Seventy-five patients had the m.3243A>G mutation and the most frequent phenotypes within the entire cohort were 14 with MELAS, 33 with MIDD, and 17 with MERRF. Urinary RBP was increased in 29 of 75 of m.3243A>G patients, whereas albumin was increased in 23 of the 75. The corresponding numbers were 16 and 14, respectively, in the 42 non-m.3243A>G patients. RBP and albumin were higher in diabetic m.3243A>G patients than in nondiabetics, but there were no significant differences across the three major clinical phenotypes. The urine proteome (mass spectrometry) and metabonome (nuclear magnetic resonance) in a subset of the m.3243A>G patients were markedly different from controls, with the most significant alterations occurring in lysosomal proteins, calcium-binding proteins, and antioxidant defenses. Differences were also found between asymptomatic m.3243A>G carriers and controls. No patients had an elevated serum creatinine level, but 14% had hyponatremia, 10% had hypophosphatemia, and 14% had hypomagnesemia. Thus, abnormalities in kidney function are common in adults with mitochondrial disease, exist in the absence of elevated serum creatinine, and are not solely explained by diabetes.

Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis

Publisher: Ovid Technologies (Wolters Kluwer Health)

Date: 23-03-2021

DOI: 10.1212/WNL.0000000000011626

Abstract: To assess long-term (2 years) effects of bimagrumab in participants with sporadic inclusion body myositis (sIBM). Participants (aged 36–85 years) who completed the core study (RESILIENT [Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients]) were invited to join an extension study. In iduals continued on the same treatment as in the core study (10 mg/kg, 3 mg/kg, 1 mg/kg bimagrumab or matching placebo administered as IV infusions every 4 weeks). The co–primary outcome measures were 6-minute walk distance (6MWD) and safety. Between November 2015 and February 2017, 211 participants entered double-blind placebo-controlled period of the extension study. Mean change in 6MWD from baseline was highly variable across treatment groups, but indicated progressive deterioration from weeks 24–104 in all treatment groups. Overall, 91.0% (n = 142) of participants in the pooled bimagrumab group and 89.1% (n = 49) in the placebo group had ≥1 treatment-emergent adverse event (AE). Falls were slightly higher in the bimagrumab 3 mg/kg group vs 10 mg/kg, 1 mg/kg, and placebo groups (69.2% [n = 36 of 52] vs 56.6% [n = 30 of 53], 58.8% [n = 30 of 51], and 61.8% [n = 34 of 55], respectively). The most frequently reported AEs in the pooled bimagrumab group were diarrhea 14.7% (n = 23), involuntary muscle contractions 9.6% (n = 15), and rash 5.1% (n = 8). Incidence of serious AEs was comparable between the pooled bimagrumab and the placebo group (18.6% [n = 29] vs 14.5% [n = 8], respectively). Extended treatment with bimagrumab up to 2 years produced a good safety profile and was well-tolerated, but did not provide clinical benefits in terms of improvement in mobility. The extension study was terminated early due to core study not meeting its primary endpoint. Clinicaltrials.gov identifier NCT02573467. This study provides Class IV evidence that for patients with sIBM, long-term treatment with bimagrumab was safe, well-tolerated, and did not provide meaningful functional benefit. The study is rated Class IV because of the open-label design of extension treatment period 2.

Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial

Publisher: Elsevier BV

Date: 09-2019

DOI: 10.1016/S1474-4422(19)30200-5

The effects of an intronic polymorphism in TOMM40 and APOE genotypes in sporadic inclusion body myositis

Publisher: Elsevier BV

Date: 04-2015

DOI: 10.1016/J.NEUROBIOLAGING.2014.12.039

Immune‐Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA–DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum

Publisher: Wiley

Date: 04-04-2017

DOI: 10.1002/ART.40045

188th ENMC International Workshop: Inclusion Body Myositis, 2–4 December 2011, Naarden, The Netherlands

Publisher: Elsevier BV

Date: 12-2013

DOI: 10.1016/J.NMD.2013.08.007

Mitochondrial ND5 Gene Variation Associated with Encephalomyopathy and Mitochondrial ATP Consumption

Publisher: Elsevier BV

Date: 12-2007

DOI: 10.1074/JBC.M704158200

Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis

Publisher: Elsevier BV

Date: 11-2016

DOI: 10.1016/J.NEUROBIOLAGING.2016.07.024

Mitochondrial Disease: Mutations and Mechanisms

Publisher: Springer Science and Business Media LLC

Date: 03-2004

DOI: 10.1023/B:NERE.0000014829.42364.DD

Abstract: The mitochondrial diseases encompass a erse group of disorders that can exhibit various combinations of clinical features. Defects in mitochondrial DNA (mtDNA) have been associated with these diseases, and studies have been able to assign biochemical defects. Deficiencies in mitochondrial oxidative phosphorylation appear to be the main pathogenic factors, although recent studies suggest that other mechanisms are involved. Reactive oxygen species (ROS) generation has been implicated in a wide variety of neurodegenerative diseases, and mitochondrial ROS generation may be an important factor in mitochondrial disease pathogenesis. Altered apoptotic signaling as a consequence of defective mitochondrial function has also been observed in both in vitro and in vivo disease models. Our current understanding of the contribution of these various mechanisms to mitochondrial disease pathophysiology will be discussed.

An Experimental Study and Mathematical Modeling of Vibration Transfer in Pistachio Trees Using an Inertia-Type Trunk Shaker and Field-Adapted Wireless Sensors

Publisher: Hindawi Limited

Date: 27-02-2022

DOI: 10.1155/2022/9966848

Abstract: Trunk shakers are the most widely used mechanical harvesting machines for harvesting nut trees, including pistachio in California. Improvement of these machines requires a better understanding of the shaking dynamics of the existing trunk shakers during harvest. In this study, the effects of four different shaking patterns on three sizes of pistachio trees of different ages, shapes, and sizes were investigated under field conditions. The vibration acceleration of the real pistachio tree was measured using a wireless network of 3-axis accelerometers installed on the shaker head and different parts of the trees during the shaking harvest. Changes in acceleration and the effect of tree morphology on the magnitude of acceleration in each pattern are presented and discussed. A new location index λ, which is based on the distance of the sensor from the shaking point and diameter of the branch at each sensor location, is introduced. This study focused on mathematical modeling of the variation and distribution of the acceleration throughout the tree canopy. The sensor location index, relative force ratio (RFR), and relative kinetic energy ratio (RKER) were defined to better understand the energy d ing in each part of the tree. The results showed that the relationship between the acceleration peaks and the sensor location index could be expressed by a third-degree polynomial function with an acceptable coefficient of determination. Under different shaking patterns, similar changes in the RFR of the tree at different locations and for different trees were observed. This finding indicates that the vibration force is significantly d ed as the distance from the shaker cl s increases. However, the RKER values at the same shaking pattern result in different effects at different points on the branches according to tree morphology.

In vivo loss of slow potassium channel activity in individuals with benign familial neonatal epilepsy in remission

Publisher: Oxford University Press (OUP)

Date: 10-2012

DOI: 10.1093/BRAIN/AWS241

Cytosolic 5′-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis

Publisher: BMJ

Date: 25-01-2017

DOI: 10.1136/ANNRHEUMDIS-2016-210282

Abstract: Autoantibodies directed against cytosolic 5′-nucleotidase 1A have been identified in many patients with inclusion body myositis. This retrospective study investigated the association between anticytosolic 5′-nucleotidase 1A antibody status and clinical, serological and histopathological features to explore the utility of this antibody to identify inclusion body myositis subgroups and to predict prognosis. Data from various European inclusion body myositis registries were pooled. Anticytosolic 5′-nucleotidase 1A status was determined by an established ELISA technique. Cases were stratified according to antibody status and comparisons made. Survival and mobility aid requirement analyses were performed using Kaplan-Meier curves and Cox proportional hazards regression. Data from 311 patients were available for analysis 102 (33%) had anticytosolic 5′-nucleotidase 1A antibodies. Antibody-positive patients had a higher adjusted mortality risk (HR 1.89, 95% CI 1.11 to 3.21, p=0.019), lower frequency of proximal upper limb weakness at disease onset (8% vs 23%, adjusted OR 0.29, 95% CI 0.12 to 0.68, p=0.005) and an increased prevalence of excess of cytochrome oxidase deficient fibres on muscle biopsy analysis (87% vs 72%, adjusted OR 2.80, 95% CI 1.17 to 6.66, p=0.020), compared with antibody-negative patients. Differences were observed in clinical and histopathological features between anticytosolic 5′-nucleotidase 1A antibody positive and negative patients with inclusion body myositis, and antibody-positive patients had a higher adjusted mortality risk. Stratification of inclusion body myositis by anticytosolic 5′-nucleotidase 1A antibody status may be useful, potentially highlighting a distinct inclusion body myositis subtype with a more severe phenotype.

Loss-of-function mutations inSCN4Acause severe foetal hypokinesia or ‘classical’ congenital myopathy

Publisher: Oxford University Press (OUP)

Date: 22-12-2015

DOI: 10.1093/BRAIN/AWV352

Reuse Feasibility of Electrocoagulated Metal Hydroxide Sludge of Textile Industry in the Manufacturing of Building Blocks

Publisher: Hindawi Limited

Date: 05-02-2013

DOI: 10.1155/2013/686981

Abstract: During the last decade, the growing load of sludge from textile industries, the top foreign exchange earning sector of Bangladesh, is a common nuisance to environmental system and community health. The present study was aimed to minimize the environmental impact from the disposal of Electrocoagulated Metal Hydroxide Sludge (EMHS) by using it as a partial substitute of clay in the manufacturing of construction material like building blocks (BBs). Different batches of normal and pressurized building blocks (NBBs and PBBs, resp.) were prepared using up to 50% EMHS with clay and then fired at a particular temperature. EMHS proportion in the mixture and firing temperature were two key factors determining the quality of BB. BB did not show any deformation or uneven surfaces at any of the examined firing temperature. At higher firing temperature and EMHS proportion, more weight loss and shrinkage of BB were noticed. Higher compressive strength and lower water adsorption were found at lower EMHS content and higher firing temperature. It was explored that NBB and PBB with 20 and 30% EMHS in clay, respectively, and fired at 1050 °C would be usable for nonloading applications namely, ornamental bricks, decoration purposes, and fence of garden.

Multicentre search for genetic susceptibility loci in sporadic epilepsy syndrome and seizure types: a case-control study

Publisher: Elsevier BV

Date: 11-2007

DOI: 10.1016/S1474-4422(07)70247-8

Solve-RD: systematic pan-European data sharing and collaborative analysis to solve rare diseases

Publisher: Springer Science and Business Media LLC

Date: 06-2021

DOI: 10.1038/S41431-021-00859-0

Abstract: For the first time in Europe hundreds of rare disease (RD) experts team up to actively share and jointly analyse existing patient’s data. Solve-RD is a Horizon 2020-supported EU flagship project bringing together clinicians, scientists, and patient representatives of 51 sites from 15 countries. Solve-RD is built upon a core group of four European Reference Networks (ERNs ERN-ITHACA, ERN-RND, ERN-Euro NMD, ERN-GENTURIS) which annually see more than 270,000 RD patients with respective pathologies. The main ambition is to solve unsolved rare diseases for which a molecular cause is not yet known. This is achieved through an innovative clinical research environment that introduces novel ways to organise expertise and data. Two major approaches are being pursued (i) massive data re-analysis of ,000 unsolved rare disease patients and (ii) novel combined -omics approaches. The minimum requirement to be eligible for the analysis activities is an inconclusive exome that can be shared with controlled access. The first preliminary data re-analysis has already diagnosed 255 cases form 8393 exomes/genome datasets. This unprecedented degree of collaboration focused on sharing of data and expertise shall identify many new disease genes and enable diagnosis of many so far undiagnosed patients from all over Europe.

Exome reanalysis and proteomic profiling identified TRIP4 as a novel cause of cerebellar hypoplasia and spinal muscular atrophy (PCH1)

Publisher: Springer Science and Business Media LLC

Date: 06-2021

DOI: 10.1038/S41431-021-00851-8

Abstract: TRIP4 is one of the subunits of the transcriptional coregulator ASC-1, a ribonucleoprotein complex that participates in transcriptional coactivation and RNA processing events. Recessive variants in the TRIP4 gene have been associated with spinal muscular atrophy with bone fractures as well as a severe form of congenital muscular dystrophy. Here we present the diagnostic journey of a patient with cerebellar hypoplasia and spinal muscular atrophy (PCH1) and congenital bone fractures. Initial exome sequencing analysis revealed no candidate variants. Reanalysis of the exome data by inclusion in the Solve-RD project resulted in the identification of a homozygous stop-gain variant in the TRIP4 gene, previously reported as disease-causing. This highlights the importance of analysis reiteration and improved and updated bioinformatic pipelines. Proteomic profile of the patient’s fibroblasts showed altered RNA-processing and impaired exosome activity supporting the pathogenicity of the detected variant. In addition, we identified a novel genetic form of PCH1, further strengthening the link of this characteristic phenotype with altered RNA metabolism.

Solving patients with rare diseases through programmatic reanalysis of genome-phenome data

Publisher: Springer Science and Business Media LLC

Date: 06-2021

DOI: 10.1038/S41431-021-00852-7

Abstract: Reanalysis of inconclusive exome/genome sequencing data increases the diagnosis yield of patients with rare diseases. However, the cost and efforts required for reanalysis prevent its routine implementation in research and clinical environments. The Solve-RD project aims to reveal the molecular causes underlying undiagnosed rare diseases. One of the goals is to implement innovative approaches to reanalyse the exomes and genomes from thousands of well-studied undiagnosed cases. The raw genomic data is submitted to Solve-RD through the RD-Connect Genome-Phenome Analysis Platform (GPAP) together with standardised phenotypic and pedigree data. We have developed a programmatic workflow to reanalyse genome-phenome data. It uses the RD-Connect GPAP’s Application Programming Interface (API) and relies on the big-data technologies upon which the system is built. We have applied the workflow to prioritise rare known pathogenic variants from 4411 undiagnosed cases. The queries returned an average of 1.45 variants per case, which first were evaluated in bulk by a panel of disease experts and afterwards specifically by the submitter of each case. A total of 120 index cases (21.2% of prioritised cases, 2.7% of all exome/genome-negative s les) have already been solved, with others being under investigation. The implementation of solutions as the one described here provide the technical framework to enable periodic case-level data re-evaluation in clinical settings, as recommended by the American College of Medical Genetics.

Disease specificity of autoantibodies to cytosolic 5′-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases

Publisher: BMJ

Date: 24-02-2015

DOI: 10.1136/ANNRHEUMDIS-2014-206691

Abstract: The diagnosis of inclusion body myositis (IBM) can be challenging as it can be difficult to clinically distinguish from other forms of myositis, particularly polymyositis (PM). Recent studies have shown frequent presence of autoantibodies directed against cytosolic 5′-nucleotidase 1A (cN-1A) in patients with IBM. We therefore, examined the autoantigenicity and disease specificity of major epitopes of cN-1A in patients with sporadic IBM compared with healthy and disease controls. Serum s les obtained from patients with IBM (n=238), PM and dermatomyositis (DM) (n=185), other autoimmune diseases (n=246), other neuromuscular diseases (n=93) and healthy controls (n=35) were analysed for the presence of autoantibodies using immunodominant cN-1A peptide ELISAs. Autoantibodies directed against major epitopes of cN-1A were frequent in patients with IBM (37%) but not in PM, DM or non-autoimmune neuromuscular diseases ( %). Anti-cN-1A reactivity was also observed in some other autoimmune diseases, particularly Sjögren's syndrome (SjS 36%) and systemic lupus erythematosus (SLE 20%). In summary, we found frequent anti-cN-1A autoantibodies in sera from patients with IBM. Heterogeneity in reactivity with the three immunodominant epitopes indicates that serological assays should not be limited to a distinct epitope region. The similar reactivities observed for SjS and SLE demonstrate the need to further investigate whether distinct IBM-specific epitopes exist.

Texture-Distortion-Constrained Joint Source-Channel Coding of Multi-View Video Plus Depth-Based 3D Video

Publisher: Institute of Electrical and Electronics Engineers (IEEE)

Date: 11-2019

DOI: 10.1109/TCSVT.2018.2877903

Solving unsolved rare neurological diseases—a Solve-RD viewpoint

Publisher: Springer Science and Business Media LLC

Date: 10-05-2021

DOI: 10.1038/S41431-021-00901-1

Ageing contributes to phenotype transition in a mouse model of periodic paralysis

Publisher: Wiley

Date: 05-05-2021

DOI: 10.1002/RCO2.41

Abstract: Periodic paralysis (PP) is a rare genetic disorder in which ion channel mutation causes episodic paralysis in association with hyper‐ or hypokalaemia. An unexplained but consistent feature of PP is that a phenotype transition occurs around the age of 40, in which the severity of potassium‐induced muscle weakness declines but onset of fixed, progressive weakness is reported. This phenotype transition coincides with the age at which muscle mass and optimal motor function start to decline in healthy in iduals. We sought to determine if the phenotype transition in PP is linked to the normal ageing phenotype transition and to explore the mechanisms involved. A mouse model of hyperkalaemic PP was compared with wild‐type littermates across a range of ages (13–104 weeks). Only male mice were used as penetrance is incomplete in females. We adapted the muscle velocity recovery cycle technique from humans to examine murine muscle excitability in vivo . We then examined changes in potassium‐induced weakness or caffeine contracture force with age using ex vivo muscle tension testing. Muscles were further characterized by either Western blot, histology or energy charge measurement. For normally distributed data, a student's t ‐test (± Welch correction) or one‐ or two‐way analysis of variance (ANOVA) was performed to determine significance. For data that were not normally distributed, Welch rank test, Mann Whitney U test or Kruskal–Wallis ANOVA was performed. When an ANOVA was significant ( P 0.05), post hoc Tukey testing was used. Both WT ( P = 0.009) and PP ( P = 0.007) muscles exhibit increased resistance to potassium‐induced weakness with age. Our data suggest that healthy‐old muscle develops mechanisms to maintain force despite sarcolemmal depolarization and sodium channel inactivation. In contrast, reduced caffeine contracture force ( P = 0.00005), skeletal muscle energy charge ( P = 0.004) and structural core pathology ( P = 0.005) were specific to Draggen muscle, indicating that they are caused, or at least accelerated by, chronic genetic ion channel dysfunction. The phenotype transition with age is replicated in a mouse model of PP. Intrinsic muscle ageing protects against potassium‐induced weakness in HyperPP mice. However, it also appears to accelerate impairment of sarcoplasmic reticulum calcium release, mitochondrial impairment and the development of core‐like regions, suggesting acquired RyR1 dysfunction as the potential aetiology. This work provides a first description of mechanisms involved in phenotype transition with age in PP. It also demonstrates how studying phenotype transition with age in monogenic disease can yield novel insights into both disease physiology and the ageing process itself.

CAV3 mutations causing exercise intolerance, myalgia and rhabdomyolysis: Expanding the phenotypic spectrum of caveolinopathies

Publisher: Elsevier BV

Date: 08-2016

DOI: 10.1016/J.NMD.2016.05.006

Abstract: Rhabdomyolysis is often due to a combination of environmental trigger(s) and genetic predisposition however, the underlying genetic cause remains elusive in many cases. Mutations in CAV3 lead to various neuromuscular phenotypes with partial overlap, including limb girdle muscular dystrophy type 1C (LGMD1C), rippling muscle disease, distal myopathy and isolated hyperCKemia. Here we present a series of eight patients from seven families presenting with exercise intolerance and rhabdomyolysis caused by mutations in CAV3 diagnosed by next generation sequencing (NGS) (n = 6). Symptoms included myalgia (n = 7), exercise intolerance (n = 7) and episodes of rhabdomyolysis (n = 2). Percussion-induced rapid muscle contractions (PIRCs) were seen in five out of six patients examined. A previously reported heterozygous mutation in CAV3 (p.T78M) and three novel variants (p.V14I, p.F41S, p.F54V) were identified. Caveolin-3 immunolabeling in muscle was normal in 3/4 patients however, immunoblotting showed more than 50% reduction of caveolin-3 in five patients compared with controls. This case series demonstrates that exercise intolerance, myalgia and rhabdomyolysis may be caused by CAV3 mutations and broadens the phenotypic spectrum of caveolinopathies. In our series, immunoblotting was a more sensitive method to detect reduced caveolin-3 levels than immunohistochemistry in skeletal muscle. Patients presenting with muscle pain, exercise intolerance and rhabdomyolysis should be routinely tested for PIRCs as this may be an important clinical clue for caveolinopathies, even in the absence of other "typical" features. The use of NGS may expand current knowledge concerning inherited diseases, and unexpected/atypical phenotypes may be attributed to well-known human disease genes.

Faulty cardiac repolarization reserve in alternating hemiplegia of childhood broadens the phenotype

Publisher: Oxford University Press (OUP)

Date: 21-08-2015

DOI: 10.1093/BRAIN/AWV243

234th ENMC International Workshop: Chaperone dysfunction in muscle disease Naarden, The Netherlands, 8–10 December 2017

Publisher: Elsevier BV

Date: 12-2018

DOI: 10.1016/J.NMD.2018.09.004

Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups

Publisher: BMJ

Date: 28-05-2019

DOI: 10.1136/ANNRHEUMDIS-2019-215046

Abstract: Idiopathic inflammatory myopathies (IIM) are a spectrum of rare autoimmune diseases characterised clinically by muscle weakness and heterogeneous systemic organ involvement. The strongest genetic risk is within the major histocompatibility complex (MHC). Since autoantibody presence defines specific clinical subgroups of IIM, we aimed to correlate serotype and genotype, to identify novel risk variants in the MHC region that co-occur with IIM autoantibodies. We collected available autoantibody data in our cohort of 2582 Caucasian patients with IIM. High resolution human leucocyte antigen (HLA) alleles and corresponding amino acid sequences were imputed using SNP2HLA from existing genotyping data and tested for association with 12 autoantibody subgroups. We report associations with eight autoantibodies reaching our study-wide significance level of p .9×10 –5 . Associations with the 8.1 ancestral haplotype were found with anti-Jo-1 (HLA-B*08:01, p=2.28×10 –53 and HLA-DRB1*03:01, p=3.25×10 –9 ), anti-PM/Scl (HLA-DQB1*02:01, p=1.47×10 –26 ) and anti-cN1A autoantibodies (HLA-DRB1*03:01, p=1.40×10 –11 ). Associations independent of this haplotype were found with anti-Mi-2 (HLA-DRB1*07:01, p=4.92×10 –13 ) and anti-HMGCR autoantibodies (HLA-DRB1*11, p=5.09×10 –6 ). Amino acid positions may be more strongly associated than classical HLA associations for ex le with anti-Jo-1 autoantibodies and position 74 of HLA-DRB1 (p=3.47×10 –64 ) and position 9 of HLA-B (p=7.03×10 –11 ). We report novel genetic associations with HLA-DQB1 anti-TIF1 autoantibodies and identify haplotypes that may differ between adult-onset and juvenile-onset patients with these autoantibodies. These findings provide new insights regarding the functional consequences of genetic polymorphisms within the MHC. As autoantibodies in IIM correlate with specific clinical features of disease, understanding genetic risk underlying development of autoantibody profiles has implications for future research.

Lanzhou University

Location: China

View Organisation

Hokkaido University

Location: Japan

View Organisation

Nanjing University Of Aeronautics And Astronautics

Location: China

View Organisation

South China Agricultural University

Location: China

View Organisation

Hokkaido University

Location: No location found

View Organisation

University College London

Location: United Kingdom of Great Britain and Northern Ireland

View Organisation

UCL Queen Square Institute Of Neurology,University College London

Location: United Kingdom of Great Britain and Northern Ireland

View Organisation

UCL Queen Square Institute Of Neurology

Location: United Kingdom of Great Britain and Northern Ireland

View Organisation

The Academy Of Medical Sciences

Location: United Kingdom of Great Britain and Northern Ireland

View Organisation

National Hospital For Neurology And Neurosurgery

Location: United Kingdom of Great Britain and Northern Ireland

View Organisation

Great Ormond Street Hospital For Children NHS Foundation Trust

Location: United Kingdom of Great Britain and Northern Ireland

View Organisation

UCL Queen Square Institute Of Neurology,University College London

Location: No location found

View Organisation